Psyber focuses on the development of brain-computer interface-enabled (BCI) digital therapeutics for treating mental health issues. On April 7th, 2021, ATAI Life Sciences acquired a majority stake in Psyber. The terms of the transaction were not disclosed.

Our clinically proven mental health solution quickly connects people to the right kind of care.

EEG-based BCI devices record electrical activity in the brain for real-time interpretation of emotional, behavioural, and mental states. Rationale: We believe in giving patients more power during their therapeutic journey, while both improving and enhancing their therapeutic experience. How it works: Psyber empowers patients who are prescribed medication to achieve better mental health outcomes by offering personalized digitally enhanced, behaviour-changing experiences that complement their medication assisted therapy. Objective: Better outcomes, a better experience and better personalized behaviour change training than existing medication or behavioral therapy solutions currently offer.